Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303Business Wire • 08/10/22
Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial ResistanceAccesswire • 07/06/22
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial ResistanceBusiness Wire • 07/06/22
Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy VolunteersBusiness Wire • 06/14/22
Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for DiabetesAccesswire • 05/17/22
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein DegradationAccesswire • 05/10/22
Evotec SE (EVO) CEO Werner Lanthaler on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/12/22
Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to CuresAccesswire • 04/12/22
Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers SquibbAccesswire • 04/08/22
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP ProgrammeAccesswire • 03/21/22
Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets DayAccesswire • 03/02/22
Evotec Expands Molecular Patient Database with Unique Nephrotic Syndrome Cohort from the University of BristolAccesswire • 03/01/22
IMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SEBusiness Wire • 02/15/22
Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 AssetsAccesswire • 02/04/22